摘要

This report describes an analysis of infants born from October 2023-March 2024 that had respiratory syncytial virus (RSV) immunization coverage through nirsevimab monoclonal antibodies or maternal vaccination.

詳細內容

This report describes an analysis of infants born from October 2023-March 2024 that had respiratory syncytial virus (RSV) immunization coverage through nirsevimab monoclonal antibodies or maternal vaccination.

關鍵發現

(需要透過 WebFetch 補充或人工審核來提取關鍵發現)

---

萃取時間: 2026-02-05T15:09:01Z 資料來源: CDC MMWR